Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA Expects FDA Decision On Lemtrada In H2-Reuters


Wednesday, 30 Jan 2013 05:31am EST 

Reuters reported that Sanofi SA expects the U.S. Food and Drug Administration (FDA) to rule on its application for multiple sclerosis treatment Lemtrada by the second half of this year. The injectable drug, chemically known as alemtuzumab, is one of the new products the French drug maker is betting on to restore growth after losing several blockbusters to generic rivals. The drug, which late-stage trials have shown helps people who have not responded to other multiple sclerosis treatments, has already been submitted for review by the European Medicines Agency. In a statement, the French drugmaker also said that an expert committee at the EMA was expected to give its opinion on the medicine in the second quarter of 2013. 

Company Quote

76.82
0.49 +0.64%
29 Jul 2014